| Name | Title | Contact Details |
|---|---|---|
Jenni Holleran |
VP, Human Resources | Profile |
Melissa Daily |
Associate Director, Human Resources | Profile |
Wendy Mastrocola |
Director, Talent & Learning | Profile |
Jennifer Grinstead |
Associate Director Human Resources | Profile |
Randi Lammert |
Director, Human Resources | Profile |
Health Plan of San Joaquin is a Stockton, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Fulton County Health Center is a full service hospital and long term care facility located in Wauseon, Ohio. They offer a wide variety of programs and services, including emergency care, surgical department, and general medical care for patients of Wau...
Life Star Response of Maryland is a Lutherville Timonium, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UpStream is the fastest-growing primary healthcare solution provider in the US. We underwrite and support the delivery of value-based care for older patients and people living with chronic conditions. By working in partnership with healthcare practices and clinics we offer a comprehensive risk-free solution for physicians that finances, delivers and sustains better outcomes for everyone. UpStream`s proven risk-free solution for physicians is called GAP-QTM (Guaranteed Advanced Payments for Quality). It combines global risk-management services with embedded professional services — all facilitated and integrated by our state of the art digital platform. GAP-QTM benefits physicians and practices through increased income and professional satisfaction. Patients benefit through reduced hospital admissions, reduced copayments, increased benefits and satisfaction, and improved health. Their informal caregivers also benefit from the significantly reduced burden and stress.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.